Treatment of Raynaud phenomenon in systemic sclerosis

被引：22

作者：

Sinnathurai, P. ^{[1
]}

Schrieber, L. ^{[1
,2
]}

机构：

[1] Royal N Shore Hosp, Dept Rheumatol, Sydney, NSW, Australia

[2] Univ Sydney, Sydney Med Sch, Sydney, NSW 2006, Australia

来源：

INTERNAL MEDICINE JOURNAL | 2013年 / 43卷 / 05期

关键词：

Raynaud phenomenon; systemic sclerosis; scleroderma; calcium channel blockers; prostacyclin analogues; ENDOTHELIN RECEPTOR ANTAGONIST; PLACEBO-CONTROLLED TRIAL; DIGITAL ULCERS; DOUBLE-BLIND; PHENOMENON SECONDARY; BOSENTAN; SCLERODERMA; MANAGEMENT; THERAPY; DISEASE;

D O I：

10.1111/imj.12082

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Systemic sclerosis is a connective tissue disease characterised by microvascular injury and excessive fibrosis of the skin and internal organs. Most patients with this condition experience Raynaud phenomenon, usually as the earliest manifestation of disease. In addition to pain and functional impairment, Raynaud phenomenon can produce tissue ischaemia resulting in digital ulceration and gangrene. Current treatments have been only moderately successful in reducing the frequency and severity of Raynaud phenomenon in patients with systemic sclerosis. This review will address treatments available for Raynaud phenomenon in systemic sclerosis.

引用

页码：476 / 483

页数：8

共 40 条

[1]

Abou-Raya A, 2008, J RHEUMATOL, V35, P1801

[2] Endothelin Receptor Antagonists for the Treatment of Raynaud's Phenomenon and Digital Ulcers in Systemic Sclerosis [J].

Arefiev, Kait ;

Fiorentino, David F. ;

Chung, Lorinda .

INTERNATIONAL JOURNAL OF RHEUMATOLOGY, 2011, 2011

[3] Adventitial stripping of the radial and ulnar arteries in Raynaud's Disease [J].

Balogh, B ;

Mayer, W ;

Vesely, M ;

Mayer, S ;

Partsch, H ;

Piza-Katzer, H .

JOURNAL OF HAND SURGERY-AMERICAN VOLUME, 2002, 27A (06) :1073-1080

[4]

Bolster M., 2011, RHEUMATOLOGY, P1373

[5] Management of Raynaud's phenomenon and digital ulcers in systemic sclerosis [J].

Botzoris, Vasileios ;

Drosos, Alexandros A. .

JOINT BONE SPINE, 2011, 78 (04) :341-346

[6] Phosphodiesterase type 5 inhibition is a novel therapeutic option in Raynaud disease [J].

Caglayan, E ;

Huntgeburth, M ;

Karasch, T ;

Weihrauch, J ;

Hunzelmann, N ;

Krieg, T ;

Erdmann, E ;

Rosenkranz, S .

ARCHIVES OF INTERNAL MEDICINE, 2006, 166 (02) :231-233

[7] MQX-503, a Novel Formulation of Nitroglycerin, Improves the Severity of Raynaud's Phenomenon A Randomized, Controlled Trial [J].

Chung, Lorinda ;

Shapiro, Lee ;

Fiorentino, David ;

Baron, Murray ;

Shanahan, Joseph ;

Sule, Sangeeta ;

Hsu, Vivien ;

Rothfield, Naomi ;

Steen, Virginia ;

Martin, Richard W. ;

Smith, Edwin ;

Mayes, Maureen ;

Simms, Robert ;

Pope, Janet ;

Kahaleh, Bashar ;

Csuka, M. E. ;

Gruber, Barry ;

Collier, David ;

Sweiss, Nadera ;

Gilbert, Adam ;

Dechow, Frederick J. ;

Gregory, Jeffrey ;

Wigley, Fredrick M. .

ARTHRITIS AND RHEUMATISM, 2009, 60 (03) :870-877

[8] Treatment of Raynaud's phenomenon with the selective serotonin reuptake inhibitor fluoxetine [J].

Coleiro, B ;

Marshall, SE ;

Denton, CP ;

Howell, K ;

Blann, A ;

Welsh, KI ;

Black, CM .

RHEUMATOLOGY, 2001, 40 (09) :1038-1043

[9] Thoracic sympathectomy for digital ischemia: A summary of evidence [J].

Coveliers, Hans M. E. ;

Hoexum, Frank ;

Nederhoed, Johanna H. ;

Wisselink, Willem ;

Rauwerda, Jan A. .

JOURNAL OF VASCULAR SURGERY, 2011, 54 (01) :273-277

[10] Phosphodiesterase-5 inhibitors for the treatment of Raynaud's: a novel indication [J].

De LaVega, Alfonso J. ;

Derk, Chris T. .

EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2009, 18 (01) :23-29

← 1 2 3 4 →